Physician profile
Krysta Berkowitz
NPI 1750983169
$1,435.75
in general payments reported to CMS, 2019-2025
31 companies · $63.25 in 2025
The $63.25 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $526 · 2022: $406 · 2023: $269 · 2024: $173 · 2025: $63.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482 · Education: $22.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.91 |
| Education | $22.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.13 | 2021-2025 | |
| Mirati Therapeutics, INC. | $139.62 | 2023-2024 | Krazati |
| Fisher & Paykel Healthcare INC | $118.65 | 2023 | Fisher & Paykel Healthcare |
| Pharmacyclics LLC, An Abbvie Company | $100.17 | 2021-2023 | Imbruvica, Epkinly |
| Merck Sharp & Dohme LLC | $84.86 | 2021-2022 | |
| Seagen INC. | $70.12 | 2021-2022 | |
| Eisai INC. | $68.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.83 | 2021-2022 | |
| Astellas Pharma US INC | $57.03 | 2021-2022 | |
| Glaxosmithkline, LLC. | $52.83 | 2021 | |
| Lilly USA, LLC | $49.72 | 2021-2022 | |
| Abiomed | $47.10 | 2024 | Impella |
| Celgene Corporation | $41.56 | 2021-2022 | |
| Epizyme, INC. | $40.04 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.96 | 2022-2024 | Krazati |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $29.96 | 2021-2022 | |
| Incyte Corporation | $29.81 | 2021-2022 | |
| Emmaus Medical, INC. | $29.53 | 2021 | |
| Amgen INC. | $28.27 | 2022 | |
| Emd Serono, INC. | $27.83 | 2021-2022 | |
| Daiichi Sankyo INC. | $22.50 | 2025 | Enhertu |
| Tersera Therapeutics LLC | $16.07 | 2022 | |
| Puma Biotechnology, INC. | $15.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.23 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.10 | 2021 | |
| Morphosys, US INC. | $15.03 | 2022 | |
| Octapharma USA, INC. | $15.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2021 | |
| Acceleron Pharma, INC. | $14.54 | 2021 | |
| Gilead Sciences, INC. | $14.39 | 2022 | |
| Genzyme Corporation | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krysta Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.